Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.38)
# 2,580
Out of 4,981 analysts
240
Total ratings
47.14%
Success rate
-2.66%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Initiates: Outperform | $300 | $266.25 | +12.68% | 1 | Sep 2, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $130 → $128 | $125.96 | +1.62% | 6 | Aug 28, 2025 | |
| CAI Caris Life Sciences | Maintains: Outperform | $33 → $40 | $33.35 | +19.94% | 2 | Aug 13, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $68 → $64 | $53.41 | +19.83% | 6 | Aug 8, 2025 | |
| AZTA Azenta | Maintains: In-Line | $35 → $33 | $30.02 | +9.93% | 8 | Aug 5, 2025 | |
| MTD Mettler-Toledo International | Maintains: Outperform | $1,280 → $1,275 | $1,268.32 | +0.53% | 11 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Outperform | $18 → $16 | $12.38 | +29.24% | 11 | Aug 4, 2025 | |
| EW Edwards Lifesciences | Maintains: In-Line | $77 → $80 | $76.65 | +4.37% | 13 | Jul 25, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $145 → $140 | $131.73 | +6.28% | 15 | Jul 17, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: In-Line | $102 → $96 | $101.07 | -5.02% | 13 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $500 → $480 | $473.23 | +1.43% | 12 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $390 → $415 | $378.25 | +9.72% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $116 → $115 | $83.62 | +37.53% | 2 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $93.68 | +13.15% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $470 → $550 | $435.58 | +26.27% | 13 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $116 → $128 | $100.39 | +27.50% | 7 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $62 → $68 | $64.07 | +6.13% | 15 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $32.06 | +43.48% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $226 | $188.28 | +20.03% | 3 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $16 | $15.16 | +5.54% | 9 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $42 | $23.70 | +77.25% | 7 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $44 → $49 | $49.31 | -0.63% | 6 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.24 | -7.41% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $96 → $85 | $78.08 | +8.86% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $112 | $100.45 | +11.50% | 6 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $202 | $136.07 | +48.45% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.27 | +144.50% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $298.49 | +18.93% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $25.51 | +119.52% | 5 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $66.12 | +141.98% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $186.11 | +55.82% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.39 | +403.60% | 1 | May 31, 2022 |
Penumbra
Sep 2, 2025
Initiates: Outperform
Price Target: $300
Current: $266.25
Upside: +12.68%
Agilent Technologies
Aug 28, 2025
Maintains: In-Line
Price Target: $130 → $128
Current: $125.96
Upside: +1.62%
Caris Life Sciences
Aug 13, 2025
Maintains: Outperform
Price Target: $33 → $40
Current: $33.35
Upside: +19.94%
Exact Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $68 → $64
Current: $53.41
Upside: +19.83%
Azenta
Aug 5, 2025
Maintains: In-Line
Price Target: $35 → $33
Current: $30.02
Upside: +9.93%
Mettler-Toledo International
Aug 4, 2025
Maintains: Outperform
Price Target: $1,280 → $1,275
Current: $1,268.32
Upside: +0.53%
Avantor
Aug 4, 2025
Maintains: Outperform
Price Target: $18 → $16
Current: $12.38
Upside: +29.24%
Edwards Lifesciences
Jul 25, 2025
Maintains: In-Line
Price Target: $77 → $80
Current: $76.65
Upside: +4.37%
Abbott Laboratories
Jul 17, 2025
Maintains: Outperform
Price Target: $145 → $140
Current: $131.73
Upside: +6.28%
Zimmer Biomet Holdings
Jul 8, 2025
Maintains: In-Line
Price Target: $102 → $96
Current: $101.07
Upside: -5.02%
Jul 8, 2025
Maintains: Outperform
Price Target: $500 → $480
Current: $473.23
Upside: +1.43%
Jul 8, 2025
Maintains: Outperform
Price Target: $390 → $415
Current: $378.25
Upside: +9.72%
Jul 8, 2025
Maintains: Outperform
Price Target: $116 → $115
Current: $83.62
Upside: +37.53%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $93.68
Upside: +13.15%
Jul 8, 2025
Maintains: In-Line
Price Target: $470 → $550
Current: $435.58
Upside: +26.27%
Jul 8, 2025
Maintains: Outperform
Price Target: $116 → $128
Current: $100.39
Upside: +27.50%
Jul 8, 2025
Maintains: In-Line
Price Target: $62 → $68
Current: $64.07
Upside: +6.13%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $32.06
Upside: +43.48%
Jul 8, 2025
Maintains: Outperform
Price Target: $230 → $226
Current: $188.28
Upside: +20.03%
Jul 8, 2025
Maintains: Outperform
Price Target: $16 → $16
Current: $15.16
Upside: +5.54%
Jul 8, 2025
Maintains: Outperform
Price Target: $44 → $42
Current: $23.70
Upside: +77.25%
Jun 4, 2025
Maintains: In-Line
Price Target: $44 → $49
Current: $49.31
Upside: -0.63%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.24
Upside: -7.41%
May 1, 2025
Maintains: Outperform
Price Target: $96 → $85
Current: $78.08
Upside: +8.86%
Apr 24, 2025
Maintains: Outperform
Price Target: $110 → $112
Current: $100.45
Upside: +11.50%
Jan 17, 2025
Maintains: Outperform
Price Target: $207 → $202
Current: $136.07
Upside: +48.45%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.27
Upside: +144.50%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $298.49
Upside: +18.93%
Oct 1, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $25.51
Upside: +119.52%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $66.12
Upside: +141.98%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $186.11
Upside: +55.82%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.39
Upside: +403.60%